Int. J. Mol. Sci. 2013, 14(8), 16087-16110; doi:10.3390/ijms140816087
Article

MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients

1 Steinbeis Transfer Center for Proteome Analysis, Schillingallee 68, 18057 Rostock, Germany 2 Department of Neurology, Division of Neuroimmunology, University of Rostock, Gehlsheimer Str. 20, 18147 Rostock, Germany 3 Institute of Immunology, University of Rostock, Schillingallee 70, 18055 Rostock, Germany 4 Institute for Biostatistics and Informatics in Medicine and Ageing Research, University of Rostock, Ernst-Heydemann-Str. 8, 18057 Rostock, Germany These authors contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 8 June 2013; in revised form: 12 July 2013 / Accepted: 26 July 2013 / Published: 5 August 2013
(This article belongs to the Special Issue Regulation by non-coding RNAs)
PDF Full-text Download PDF Full-Text [685 KB, uploaded 5 August 2013 15:44 CEST]
Abstract: MicroRNAs (miRNAs) are small non-coding RNA molecules acting as post-transcriptional regulators of gene expression. They are involved in many biological processes, and their dysregulation is implicated in various diseases, including multiple sclerosis (MS). Interferon-beta (IFN-beta) is widely used as a first-line immunomodulatory treatment of MS patients. Here, we present the first longitudinal study on the miRNA expression changes in response to IFN-beta therapy. Peripheral blood mononuclear cells (PBMC) were obtained before treatment initiation as well as after two days, four days, and one month, from patients with clinically isolated syndrome (CIS) and patients with relapsing-remitting MS (RRMS). We measured the expression of 651 mature miRNAs and about 19,000 mRNAs in parallel using real-time PCR arrays and Affymetrix microarrays. We observed that the up-regulation of IFN-beta-responsive genes is accompanied by a down-regulation of several miRNAs, including members of the mir-29 family. These differentially expressed miRNAs were found to be associated with apoptotic processes and IFN feedback loops. A network of miRNA-mRNA target interactions was constructed by integrating the information from different databases. Our results suggest that miRNA-mediated regulation plays an important role in the mechanisms of action of IFN-beta, not only in the treatment of MS but also in normal immune responses. miRNA expression levels in the blood may serve as a biomarker of the biological effects of IFN-beta therapy that may predict individual disease activity and progression.
Keywords: interferon-beta; multiple sclerosis; peripheral blood; microRNA; gene expression

Supplementary Files

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Hecker, M.; Thamilarasan, M.; Koczan, D.; Schröder, I.; Flechtner, K.; Freiesleben, S.; Füllen, G.; Thiesen, H.-J.; Zettl, U.K. MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients. Int. J. Mol. Sci. 2013, 14, 16087-16110.

AMA Style

Hecker M, Thamilarasan M, Koczan D, Schröder I, Flechtner K, Freiesleben S, Füllen G, Thiesen H-J, Zettl UK. MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients. International Journal of Molecular Sciences. 2013; 14(8):16087-16110.

Chicago/Turabian Style

Hecker, Michael; Thamilarasan, Madhan; Koczan, Dirk; Schröder, Ina; Flechtner, Kristin; Freiesleben, Sherry; Füllen, Georg; Thiesen, Hans-Jürgen; Zettl, Uwe K. 2013. "MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients." Int. J. Mol. Sci. 14, no. 8: 16087-16110.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert